

Press release 2019-02-01

Quickcool AB: Directed share issue to the European High Growth Opportunities Securitization Fund is registered

The directed share issue, with exemption from the shareholders' preferential rights, addressed to the European High Growth opportunities Securitization Fund, has been registered.

QuickCool AB (publ) ("Quickcool") published a press release on 18 January 2019 that the Board of Directors had taken the decision to address a directed share issue, with exemption from the shareholders' preferential rights, to the European High Growth Opportunities Securitization Fund. It has now been registered.

Through the directed share issue, 416 667 shares have been issued which corresponds to an increase in the share capital by SEK 250 000,20. The payment of the shares has been made by offsetting the debt. For each share, SEK 0.60 has been paid, which corresponds to a total amount of SEK 250 000,20.

After registering with the Swedish Companies Registration Office, Quickcool's total share capital amounts to SEK 14 674 368 and the total number of shares to 24 457 280.

For additional information, please contact:

Fredrik Radencrantz, CEO

Phone: 046-286 38 40

E-mail: fredrik.radencrantz@quickcool.se

This information is such that QuickCool AB is required to make public in accordance with the EU's market abuse regulation (MAR). The information was made publicly available by the Company's contact person on 01 February, 2018.

QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool's solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool's Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se